Menu
← Oncology Approval Tracker
FDA DECISION ·
Vyloy
zolbetuximab-clzb · Astellas Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment with fluoropyrimidine and platinum chemotherapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma that is CLDN18.2 positive on an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The CLDN18.2 antibody opens a new biomarker-based option in first-line gastric and junctional cancer.
What research teams should watch
Plan HER2 and CLDN18.2 testing together and prepare antiemetic and infusion workflows for nausea and vomiting.
PRIMARY RECORDS